FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.
연구 도서관으로 돌아가기
GLP1-RALiraglutideSemaglutide

Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.

May 17, 2026
Share

원본 논문

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen Anders Boisen et al.Obesity surgery2023
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 위의 원본 논문에서 발견한 결과를 피테이드 연구 커뮤니티에게 이해하기 쉬운 언어로 분해합니다. 우리의 목표는 가장 중요한 사항을 강조하는 것입니다 — 실용적 의미, 증거의 강도, 그리고 현재 진행 중인 연구에 대한 의미.

GLP-1 Receptor Agonists Show Promise in Tackling Weight Regain After Bariatric Surgery

Published: May 17, 2026 | Source: Obesity surgery (2023) | Category: GLP1-RA, Liraglutide, Semaglutide

Overview

A recent study published in Obesity Surgery suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as liraglutide and semaglutide, can help patients who have regained weight after bariatric surgery to lose a significant portion of the regained weight within six months. This finding is crucial for those seeking effective treatments for weight regain following surgical interventions.

Study Background

Weight regain after bariatric surgery is a common issue, affecting up to one-third of patients. While GLP-1 RAs are known to be effective in managing type 2 diabetes and obesity, their role in treating weight regain specifically after bariatric surgery was less clear until now. This retrospective observational study aimed to fill this knowledge gap by examining the efficacy of liraglutide and semaglutide for patients who had regained weight post-surgery.

What the Research Found

The study involved 50 patients (82% female) at a Swiss bariatric reference center, with an average age of 47 years. Before treatment with GLP-1 RAs, these patients had an average body weight of 90.5 kg and a BMI of 34.0 kg/m². After six months of treatment (liraglutide: n=29; semaglutide: n=21), the median weight loss was substantial, with two-thirds of the regained weight being lost.

What This Means for Peptide Users

For individuals who have experienced weight regain after bariatric surgery, this study provides hope and a new therapeutic option. GLP-1 RAs can be an effective tool in helping these patients achieve significant weight loss, thereby improving their overall health outcomes and reducing the risk of obesity-related complications.

Limitations and Caveats

While promising, this study has several limitations that must be acknowledged. It was conducted at a single center with a relatively small sample size, which limits its generalizability to broader populations. Additionally, the retrospective nature of the research means there could be uncontrolled variables influencing the results. Randomized controlled trials are needed to confirm these findings and establish GLP-1 RAs as standard treatment options for weight regain after bariatric surgery.

How This Compares to Previous Research

Previous studies have highlighted the efficacy of GLP-1 RAs in treating obesity and type 2 diabetes, but this is one of the first to focus specifically on their role in managing weight regain post-bariatric surgery. The results align with earlier research showing that these peptides can induce significant weight loss, although the specific context of bariatric surgery adds a new dimension to our understanding.

Our Analysis

PeptideVault views this study as an important step forward in addressing the challenges faced by patients who experience weight regain after bariatric surgery. The findings are encouraging and provide a basis for further research. However, due to the limitations mentioned, it is crucial that future studies employ randomized controlled trial designs to validate these results.

Key Takeaways

  • GLP-1 RAs can help patients lose significant amounts of regained weight within six months after bariatric surgery.
  • The study highlights a need for larger-scale clinical trials to confirm the efficacy and safety of GLP-1 RAs in this specific patient population.
  • For now, healthcare providers should consider these findings as part of an evolving understanding of GLP-1 RA's potential benefits beyond traditional indications like diabetes and obesity.

Original Source

Citation: Jensen Anders Boisen, Renström Frida, Aczél Stefan et al. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.. Obesity surgery. DOI: 10.1007/s11695-023-06484-8

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

이 분석은 Peptide Contacts 연구 팀에 의해 작성되었습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하기 위해 원본 논문 전체 방법론 및 데이터는 여기에서 확인하실 수 있습니다. 원래 출판물은 {source}에서 확인하실 수 있습니다. PubMed.

관련 연구

Comments

Sign in to join the discussion

이 분석은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.